Neuronetics Stock Forecast, Price & News

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STIM shares have increased by 927.5% and is now trading at $21.27.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Neuronetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neuronetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Neuronetics.

Neuronetics, Inc. (NASDAQ:STIM) issued its earnings results on Monday, November, 2nd. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.13. The firm earned $12.45 million during the quarter, compared to analyst estimates of $11.17 million. Neuronetics had a negative net margin of 61.44% and a negative trailing twelve-month return on equity of 88.76%.
View Neuronetics' earnings history.

Neuronetics issued an update on its fourth quarter 2020 After-Hours earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $15-15.5 million, compared to the consensus revenue estimate of $13.26 million.

4 brokers have issued twelve-month price objectives for Neuronetics' shares. Their forecasts range from $8.00 to $27.00. On average, they anticipate Neuronetics' share price to reach $17.75 in the next year. This suggests that the stock has a possible downside of 16.5%.
View analysts' price targets for Neuronetics or view Wall Street analyst' top-rated stocks.

Neuronetics saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 576,700 shares, a decline of 15.3% from the December 15th total of 681,100 shares. Based on an average daily volume of 232,400 shares, the days-to-cover ratio is presently 2.5 days. Currently, 4.5% of the company's shares are sold short.
View Neuronetics' Short Interest.

Some companies that are related to Neuronetics include Inovio Pharmaceuticals (INO), Atrion (ATRI), Luminex (LMNX), Cerus (CERS), Alphatec (ATEC), GenMark Diagnostics (GNMK), Tactile Systems Technology (TCMD), SI-BONE (SIBN), OraSure Technologies (OSUR), MiMedx Group (MDXG), CryoLife (CRY), LeMaitre Vascular (LMAT), Intersect ENT (XENT), OrthoPediatrics (KIDS) and Orthofix Medical (OFIX).
View all of STIM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include David J Yvars Group (0.27%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe and William Andrew Macan.
View institutional ownership trends for Neuronetics.

STIM stock was bought by a variety of institutional investors in the last quarter, including David J Yvars Group. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, and William Andrew Macan.
View insider buying and selling activity for Neuronetics or or view top insider-buying stocks.

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $21.27.

Neuronetics has a market capitalization of $403.60 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 122 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202 or via email at [email protected]